Trial Profile
Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Pharmacokinetics
- 03 Nov 2016 New trial record